CD33 and acute myeloid leukemia: A preclinical experiment evaluated six CD33 CAR constructs using scFv containing CD3ζ domain and showed antileukemia activity, which results in a clinical trial for relapsed/refractory childhood AML (NCT03971799) (Qin et al., 2021).